CYP2D6基因多态性与抗精神病药物的个体化应用

摘要/Abstract

摘要： CYP2D6是一种重要的细胞色素P450酶,存在着显著的基因多态性。CYP2D6在抗精神病类药物的代谢中发挥着重要作用,与许多抗精神病药物药动学及药效学的个体间变异存在着密切联系,检测CYP2D6基因型有助于患者抗精神病药物治疗方案的选择和调整,提高用药的安全性和有效性。本文综述CYP2D6基因多态性对抗精神病药物的药动学、不良反应及药物相互作用的影响,探讨了CYP2D6基因型检测在抗精神病个体化治疗中的应用前景。

关键词: CYP2D6, 基因多态性, 抗精神病药物, 药动学, 不良反应

Abstract: CYP2D6 is one of the most important cytochrome P450 enzymes. There is remarkable genetic polymorphism of CYP2D6. CYP2D6 play an important role in the metabolism of antipsychotics, and has significant correlation with the inter-individual difference of pharmacokinetics and pharmacodynamics of antipsychotics. Determination of CYP2D6 genotypes is helpful in the selection and regulation of antipsychotic therapy regimen for the elevation of efficiency and safety. The influence of CYP2D6 genetic polymorphism on the pharmacokinetics, adverse effect and drug-drug interaction was reviewed and the usefulness of CYP2D6 genotyping in the personalized antipsychotic therapy was discussed.

Key words: CYP2D6, Genetic polymorphism, Antipsychotics, Pharmacokinetics, Adverse drug reaction

中图分类号:

R969

陈冰, 蔡卫民, 杨婉花. CYP2D6基因多态性与抗精神病药物的个体化应用[J]. 中国临床药理学与治疗学, 2012, 17(9): 1067-1074.

CHEN Bing, CAI Wei-min, YANG Wan-hua. Genetic polymorphism of CYP2D6 and its influence on the personalized usage of antipsychotics[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(9): 1067-1074.

参考文献

[1] Mihaljevic' -Peles A, Sagud M, Bozina N, et al. Pharmacogenetics and antipsychotics in the light of personalized pharmacotherapy[J]. Psychiatr Danub, 2010,22(2): 335-337.
[2] Lohoff FW.The future of psychiatric pharmacogenomics[J]. Pharmacogenomics, 2011, 12(7): 927-929.
[3] Zhou SF.Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I[J]. Clin Pharmacokinet, 2009, 48(11): 689-723.
[4] Zhou SF.Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II[J]. Clin Pharmacokinet, 2009, 48(12): 761-804.
[5] Cai WM, Chen B, Zhang WX.Frequency of CYP2D6 *10 and *14 alleles and their influence on the metabolic activity of CYP2D6 in a healthy Chinese population[J]. Clin Pharmacol Ther, 2007, 81(1): 95-98.
[6] Ingelman-Sundberg M, Daly AK, Nebert DW. Homepage of the human cytochrome P450 (CYP) allele nomenclature committee[EB/OL]. http://www.imm.ki.se/CYPalleles.
[7] Plesnicar BK, Dolzan V, Zalar B.CYP2D6 polymorphism and antipsychotic therapy[J]. Psychiatr Danub, 2008, 20(3): 369-371.
[8] Brockmoller J, Kirchheiner J, Schmider J, et al.The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment[J]. Clin Pharmacol Ther, 2002,72(4): 438-452.
[9] Someya T, Shimoda K, Suzuki Y, et al.Effect of CYP2D6 genotypes on the metabolism of haloperidol in a Japanese psychiatric population[J]. Neuropsychopharmacology, 2003, 28(8): 1501-1505.
[10] Panagiotidis G, Arthur HW, Lindh JD, et al.Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome[J]. Ther Drug Monit, 2007, 29(4): 417-422.
[11] Novalbos J, López-Rodríguez R, Román M, et al.Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers[J]. J Clin Psychopharmacol, 2010,30(5): 504-511.
[12] Xiang Q, Zhao X, Zhou Y, et al.Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety[J]. J Clin Pharmacol, 2010, 50(6): 659-666.
[13] Hinrichs JW, Loovers HM, Scholten B, et al.Semi-quantitative CYP2D6 gene doses in relation to metabolic ratios of psychotropics[J]. Eur J Clin Pharmacol, 2008, 64(10): 979-986.
[14] Ozdemir V, Bertilsson L, Miura J, et al.CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited[J]. Pharmacogenet Genomics, 2007, 17(5): 339-347.
[15] Jaanson P, Marandi T, Kiivet RA, et al.Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype[J]. Psychopharmacology (Berl),2002, 162(1): 67-73.
[16] Jaquenoud Sirot E, Knezevic B, Morena GP, et al.ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine[J]. J Clin Psychopharmacol, 2009, 29(4): 319-326.
[17] Kobylecki CJ, Jakobsen KD, Hansen T, et al.CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study[J]. Neuropsychobiology, 2009, 59(4): 222-226.
[18] de Leon J, Susce MT, Pan RM, et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation[J]. J Clin Psychiatry, 2005, 66(1): 15-27.
[19] Liou YJ, Wang YC, Bai YM, et al.Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients[J]. Neuropsychobiology, 2004, 49(4): 167-173.
[20] Patsopoulos NA, Ntzani EE, Zintzaras E, et al.CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis[J]. Pharmacogenet Genomics, 2005, 15(3): 151-158.
[21] De Hert M, Detraux J, van Winkel R. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs[J]. Nat Rev Endocrinol, 2011, 8(2): 114-126.
[22] Dorado P, Berecz R, Pehas-Lledó EM, et al.Antipsychotic drugs and QTc prolongation: the potential role of CYP2D6 genetic polymorphism[J]. Expert Opin Drug Metab Toxicol, 2007, 3(1): 9-19.
[23] Llerena A, Berecz R, de la Rubia A, et al. QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients[J]. J Psychopharmacol, 2002,16(4): 361-364.
[24] Llerena A, Berecz R, Dorado P, et al.QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations[J]. J Psychopharmacol, 2004, 18(2): 189-193.
[25] Thanacoody RH, Daly AK, Reilly JG, et al.Factors affecting drug concentrations and QT interval during thioridazine therapy[J]. Clin Pharmacol Ther, 2007, 82(5): 555-565.
[26] Risselada AJ, Mulder H, Heerdink ER, et al.Pharmacogenetic testing to predict antipsychotic-induced weight gain: a systematic review[J]. Pharmacogenomics, 2011, 12(8): 1213-1227.
[27] Mannheimer B, von Bahr C, Pettersson H, et al. Impact of multiple inhibitors or substrates of cytochrome P450 2D6 on plasma risperidone levels in patients on polypharmacy[J]. Ther Drug Monit, 2008, 30(5): 565-569.
[28] Bondolfi G, Eap CB, Bertschy G, et al.The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients[J].Pharmacopsychiatry, 2002, 35(2): 50-56.
[29] Park JY, Shon JH, Kim KA, et al.Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects[J]. J Clin Psychopharmacol, 2006, 26(2): 135-142.
[30] Llerena A, Berecz R, de la Rubia A, et al. Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes[J]. Ther Drug Monit, 2001, 23(6): 616-620.
[31] Oosterhuis M, Van De Kraats G, et al. Safety of aripiprazole: high serum levels in a CYP2D6 mutated patient[J]. Am J Psychiatry,2007, 164(1): 175.
[32] Ochi S, Kawasoe K, Abe M, et al. A case study: neuroleptic malignant syndrome with risperidone and CYP2D6 gene variation[J]. Gen Hosp Psychiatry, 2011, 33(6): 640.e1-2.
[33] Spina E, Scordo MG, Avenoso A, et al.Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity[J]. J Clin Psychopharmacol, 2001, 21(1): 108-109.